A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection

References

• Neiman P, Wasserman PB, Wentworth BB, et al. Interstitial pneumonia and cytomegalovirus infection as complications of human marrow transplantation. Transplantation. 1973;15(5):478-485.
   Google Scholar
• Chen K, Cheng MP, Hammond SP, et al. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. Blood Adv. 2018;2(16):2159–2175.
   PubMed Web of Science ®Google Scholar
• Goodrich JM, Bowden RA, Fisher L, et al. GAnciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118(3):173–178.
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333–360.
   PubMed Web of Science ®Google Scholar
• Jain NA, Lu K, Ito S, et al. The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches. Cytotherapy. 2014;16(7):927–933.
   PubMed Web of Science ®Google Scholar
• Robin C, Hemery F, Dindorf C, et al. Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients. BMC Infect Dis. 2017;17(1):747.
   PubMed Web of Science ®Google Scholar
• Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–2438.
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011;118(5):1402–1412.
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood. 2013;122(7):1316–1324.
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119–127.
   PubMed Web of Science ®Google Scholar
• Martin SI, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2006;43(1):16–24.
   PubMed Web of Science ®Google Scholar
• Chan ST, Logan AC. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: why the quest for meaningful prophylaxis still matters. Blood Rev. 2017;31(3):173–183.
   PubMed Web of Science ®Google Scholar
• Milano F, Pergam SA, Xie H, et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood. 2011;118(20):5689–5696.
   PubMed Web of Science ®Google Scholar
• Hill JA, Pergam SA, Cox E, et al. A modified intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Biol Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2018. In press. doi: 10.1016/j.bbmt.2018.05.008
   Google Scholar
• Hammerstrom AE, Lombardi LR, Pingali SR, et al. Prevention of cytomegalovirus reactivation in haploidentical stem cell transplantation. Biol Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2018;24(2):353–358.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11(4):284–292.
   PubMed Web of Science ®Google Scholar
• Marty FM, Boeckh M. Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed? Curr Opin Virol. 2011;1(6):555–562.
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369(13):1227–1236.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplantation: off J Am Soc Transplant Am Soc Transpl Surgeons. 2012;12(11):3021–3030.
   Google Scholar
• Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010;54(3):1290–1297.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–2444.
   PubMed Web of Science ®Google Scholar
• Goldner T, Hempel C, Ruebsamen-Schaeff H, et al. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58(1):610–613.
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6);900–931.
   Google Scholar
• Boeckh M, Murphy WJ, Peggs KS. Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2015;21(1):24–29.
   PubMed Web of Science ®Google Scholar
• Razonable RR. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients. Infect Dis Clin North Am. 2013;27(2):317–342.
   PubMed Web of Science ®Google Scholar
• Plotkin S. The history of vaccination against cytomegalovirus. Med Microbiol Immunol. 2015;204(3):247–254.
   PubMed Web of Science ®Google Scholar
• Schleiss MR. Cytomegalovirus vaccines under clinical development. J Virus Eradication. 2016;2(4):198–207.
   PubMed Web of Science ®Google Scholar
• Ross SA, Arora N, Novak Z, et al. Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis. 2010;201(3):386–389.
   PubMed Web of Science ®Google Scholar
• La Rosa C, Diamond DJ. The immune response to human CMV. Future Virol. 2012;7(3):279–293.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med. 1991;114(7):525–531.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation. 1994;58(11):1176–1178.
   PubMed Web of Science ®Google Scholar
• Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377(9773):1256–1263.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(4):290–299.
   PubMed Web of Science ®Google Scholar
• Gamadia LE, Rentenaar RJ, Baars PA, et al. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood. 2001;98(3):754–761.
   PubMed Web of Science ®Google Scholar
• La Rosa C, Limaye AP, Krishnan A, et al. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. Transpl Int: Off J Eur Soc Transplant. 2011;24(9):920–931.
   PubMed Web of Science ®Google Scholar
• La Rosa C, Limaye AP, Krishnan A, et al. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis. 2007;195(5):633–644.
   PubMed Web of Science ®Google Scholar
• Gratama JW, Boeckh M, Nakamura R, et al. Immune monitoring with iTAg MHC tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood. 2010;116(10):1655–1662.
   PubMed Web of Science ®Google Scholar
• Zhou W, Longmate J, Lacey SF, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood. 2009;113(25):6465–6476.
   PubMed Web of Science ®Google Scholar
• Wussow F, Chiuppesi F, Martinez J, et al. Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog. 2014;10(11):e1004524.
   PubMed Web of Science ®Google Scholar
• Freed DC, Tang Q, Tang A, et al. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci U S A. 2013;110(51):E4997–5005.
   PubMed Web of Science ®Google Scholar
• Nakamura R, La Rosa C, Longmate J, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol. 2016;3(2):e87–98.
   PubMed Web of Science ®Google Scholar
• Pass RF. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J Clin Virol: Off Publ Pan Am Soc Clin Virol. 2009;46(Suppl 4):S73–76.
   Google Scholar
• Bernstein DI, Munoz FM, Callahan ST, et al. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial. Vaccine. 2016;34(3):313–319.
   PubMed Web of Science ®Google Scholar
• Isaacson MK, Compton T. Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J Virol. 2009;83(8):3891–3903.
   PubMed Web of Science ®Google Scholar
• Mumtaz K, Faisal N, Husain S, et al. Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis. Am J Transplantation: off J Am Soc Transplant Am Soc Transpl Surgeons. 2015;15(2):472–481.
   Google Scholar
• Kabanova A, Perez L, Lilleri D, et al. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci U S A. 2014;111(50):17965–17970.
   PubMed Web of Science ®Google Scholar
• Gerna G, Revello MG, Baldanti F, et al. The pentameric complex of human cytomegalovirus: cell tropism, virus dissemination, immune response and vaccine development. J Gen Virol. 2017;98(9):2215–2234.
   PubMed Web of Science ®Google Scholar
• Wloch MK, Smith LR, Boutsaboualoy S, et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis. 2008;197(12):1634–1642.
   PubMed Web of Science ®Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202(5):673–685.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Budde K, Merville P, et al. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. Am J Transplantation: off J Am Soc Transplant Am Soc Transpl Surgeons. 2018;00:1–10.
   Google Scholar
• Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines. 2016;15(3):313–329.
   PubMed Web of Science ®Google Scholar
• Diamond DJ, York J, Sun JY, et al. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood. 1997;90(5):1751–1767.
   PubMed Web of Science ®Google Scholar
• Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol. 1996;70(11):7569–7579.
   PubMed Web of Science ®Google Scholar
• Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol. 2012;19(4):324–335.
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99(11):3916–3922.
   PubMed Web of Science ®Google Scholar
• La Rosa C, Longmate J, Lacey SF, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis. 2012;205(8):1294–1304.
   PubMed Web of Science ®Google Scholar
• Bowden RA, Fisher LD, Rogers K, et al. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis. 1991;164(3):483–487.
   PubMed Web of Science ®Google Scholar
• La Rosa C, Longmate J, Martinez J, et al. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. Blood. 2017;129(1):114–125.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhou W, Srivastava T, et al. A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. Virology. 2008;377(2):379–390.
   PubMed Web of Science ®Google Scholar
• Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med. 2005;201(7):1031–1036.
   PubMed Web of Science ®Google Scholar
• Lacey SF, La Rosa C, Zhou W, et al. Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J Infect Dis. 2006;194(10):1410–1421.
   PubMed Web of Science ®Google Scholar
• Gimenez E, Munoz-Cobo B, Solano C, et al. Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8(+) T cells that are associated with protection from and control of CMV DNAemia after allogeneic stem cell transplantation. Transpl Infect Dis: Off J Transplant Soc. 2015;17(3):361–370.
   PubMed Web of Science ®Google Scholar
• Gratama JW, Brooimans RA, van der Holt B, et al. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry B Clin Cytom. 2008;74(4):211–220.
   PubMedGoogle Scholar
• Cottingham MG, Carroll MW. Recombinant MVA vaccines: dispelling the myths. Vaccine. 2013;31(39):4247–4251.
   PubMed Web of Science ®Google Scholar
• Walsh SR, Wilck MB, Dominguez DJ, et al. Safety and immunogenicity of modified vaccinia ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis. 2013;207(12):1888–1897.
   PubMed Web of Science ®Google Scholar
• Ramanathan M, Teira P, Battiwalla M, et al. Early CMV reactivation still remains a cause of increased transplant related mortality in the current era: a CIBMTR analysis. Blood. 2014;124(21): 47 (abstr).
   Web of Science ®Google Scholar
• Laberko A, Bogoyavlenskaya A, Shelikhova L, et al. Risk factors for and the clinical impact of cytomegalovirus and epstein-barr virus infections in pediatric recipients of TCR-alpha/beta- and CD19-depleted grafts. Biol Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2017;23(3):483–490.
   PubMed Web of Science ®Google Scholar
• Qayed M, Khurana M, Hilinski J, et al. Risk for CMV reactivation in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2015;62(2):364–366.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151–169.
   PubMed Web of Science ®Google Scholar
• Suessmuth Y, Mukherjee R, Watkins B, et al. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRbeta repertoire. Blood. 2015;125(25):3835–3850.
   PubMed Web of Science ®Google Scholar
• Horn B, Bao L, Dunham K, et al. Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution. Pediatr Infect Dis J. 2009;28(1):65–67.
   PubMed Web of Science ®Google Scholar
• Storek J, Dawson MA, Lim LC, et al. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation. Bone Marrow Transplant. 2004;33(3):337–346.
   PubMed Web of Science ®Google Scholar
• Crocchiolo R, Bramanti S, Vai A, et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis: Off J Transplant Soc. 2015;17(2):242–249.
   PubMed Web of Science ®Google Scholar
• Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014;124(3):334–343.
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Slade M, DiPersio JF, et al. Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Haematologica. 2016;101(11):e465–e468.
   PubMed Web of Science ®Google Scholar
• Ludwig A, Hengel H. Epidemiological impact and disease burden of congenital cytomegalovirus infection in Europe. Euro surveillance: Bull Eur sur les Mal transmissibles Eur communicable Dis Bull. 2009;14(9):26–32.
   Google Scholar
• Manicklal S, Emery VC, Lazzarotto T, et al. The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26(1):86–102.
   PubMed Web of Science ®Google Scholar
• Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17(4):253–276.
   PubMed Web of Science ®Google Scholar
• Britt W. Controversies in the natural history of congenital human cytomegalovirus infection: the paradox of infection and disease in offspring of women with immunity prior to pregnancy. Med Microbiol Immunol. 2015.
   PubMed Web of Science ®Google Scholar
• Boppana SB, Ross SA, Fowler KB. Congenital cytomegalovirus infection: clinical outcome. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2013;57(Suppl 4):S178–181.
   PubMed Web of Science ®Google Scholar
• Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17(5):355–363.
   PubMed Web of Science ®Google Scholar
• Pass RF, Anderson B. Mother-to-child transmission of cytomegalovirus and prevention of congenital infection. J Pediatric Infect Dis Soc. 2014;3(Suppl 1):S2–S6.
   PubMedGoogle Scholar
• Itell HL, Nelson CS, Martinez DR, et al. Maternal immune correlates of protection against placental transmission of cytomegalovirus. Placenta. 2017;60(Suppl 1):S73-S9.
   PubMed Web of Science ®Google Scholar
• Yamamoto AY, Mussi-Pinhata MM, Boppana SB, et al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol. 2010;202(3):297, e291–298.
   Web of Science ®Google Scholar
• Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. Jama. 2003;289(8):1008–1011.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Starr SE, Friedman HM, et al. Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis. 1990;12(Suppl 7):S827–838.
   PubMedGoogle Scholar
• Plotkin SA, Boppana SB. Vaccination against the human cytomegalovirus. Vaccine. 2018. In Press.  doi: 10.1016/j.vaccine.2018.02.089
   PubMedGoogle Scholar
• Permar SR, Schleiss MR, Plotkin SA. Advancing our understanding of protective maternal immunity as a guide for development of vaccines to reduce congenital cytomegalovirus infections. J Virol. 2018;92:7.
   Web of Science ®Google Scholar
• Renzette N, Pokalyuk C, Gibson L, et al. Limits and patterns of cytomegalovirus genomic diversity in humans. Proc Natl Acad Sci U S A. 2015;112(30):E4120–4128.
   PubMed Web of Science ®Google Scholar
• Arav-Boger R. Strain variation and disease severity in congenital cytomegalovirus infection: in search of a viral marker. Infect Dis Clin North Am. 2015;29(3):401–414.
   PubMed Web of Science ®Google Scholar
• Neff BJ, Weibel RE, Buynak EB, et al. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med. 1979;160(1):32–37.
   PubMed Web of Science ®Google Scholar
• Adler SP, Starr SE, Plotkin SA, et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis. 1995;171(1):26–32.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Huang ES. Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis. 1985;152(2):395–397.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Starr SE, Friedman HM, et al. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis. 1989;159(5):860–865.
   PubMed Web of Science ®Google Scholar
• Cha TA, Tom E, Kemble GW, et al. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol. 1996;70(1):78–83.
   PubMed Web of Science ®Google Scholar
• Prichard MN, Penfold ME, Duke GM, et al. A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev Med Virol. 2001;11(3):191–200.
   PubMed Web of Science ®Google Scholar
• Suarez NM, Lau B, Kemble GM, et al. Genomic analysis of chimeric human cytomegalovirus vaccine candidates derived from strains towne and Toledo. Virus Genes. 2017;53(4):650–655.
   PubMed Web of Science ®Google Scholar
• Heineman TC, Schleiss M, Bernstein DI, et al. A phase 1 study of 4 live, recombinant human cytomegalovirus towne/toledo chimeric vaccines. J Infect Dis. 2006;193(10):1350–1360.
   PubMed Web of Science ®Google Scholar
• Adler SP, Manganello AM, Lee R, et al. A phase 1 study of four live, recombinant human cytomegalovirus towne/toledo chimera vaccines in CMV seronegative men. J Infect Dis. 2016.
   Web of Science ®Google Scholar
• Wang D, Freed DC, He X, et al. A replication-defective human cytomegalovirus vaccine for prevention of congenital infection. Sci Transl Med. 2016;8(362):362ra145.
   PubMed Web of Science ®Google Scholar
• Adler S, Lewis N, Conlon A, et al. Phase 1 clinical trial of a replication-defective human cytomegalovirus (CMV) vaccine. Open Forum Infect Dis. 2017;4(Suppl1):S308–S309.
   Google Scholar
• McCormick AL, Mocarski ES. The immunological underpinnings of vaccinations to prevent cytomegalovirus disease. Cell Mol Immunol. 2015;12(2):170–179.
   PubMed Web of Science ®Google Scholar
• Dumont J, Euwart D, Mei B, et al. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotechnol. 2016;36(6):1110–1122.
   PubMed Web of Science ®Google Scholar
• Britt WJ, Vugler L, Butfiloski EJ, et al. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol. 1990;64(3):1079–1085.
   PubMed Web of Science ®Google Scholar
• Pass RF, Duliege AM, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis. 1999;180(4):970–975.
   PubMed Web of Science ®Google Scholar
• Frey SE, Harrison C, Pass RF, et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis. 1999;180(5):1700–1703.
   PubMed Web of Science ®Google Scholar
• Sabbaj S, Pass RF, Goepfert PA, et al. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis. 2011;203(11):1534–1541.
   PubMed Web of Science ®Google Scholar
• Mitchell DK, Holmes SJ, Burke RL, et al. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J. 2002;21(2):133–138.
   PubMed Web of Science ®Google Scholar
• Baraniak I, Kropff B, Ambrose L, et al. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies. Proc Natl Acad Sci U S A. 2018;115(24):6273–6278.
   PubMed Web of Science ®Google Scholar
• Nelson CS, Huffman T, Jenks JA, et al. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc Natl Acad Sci U S A. 2018;115(24):6267–6272.
   PubMed Web of Science ®Google Scholar
• Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009;360(12):1191–1199.
   PubMed Web of Science ®Google Scholar
• Vanarsdall AL, Johnson DC. Human cytomegalovirus entry into cells. Curr Opin Virol. 2012;2(1):37–42.
   PubMed Web of Science ®Google Scholar
• Hahn G, Revello MG, Patrone M, et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol. 2004;78(18):10023–10033.
   PubMed Web of Science ®Google Scholar
• Ryckman BJ, Jarvis MA, Drummond DD, et al. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol. 2006;80(2):710–722.
   PubMed Web of Science ®Google Scholar
• Macagno A, Bernasconi NL, Vanzetta F, et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol. 2010;84(2):1005–1013.
   PubMed Web of Science ®Google Scholar
• Chiuppesi F, Wussow F, Johnson E, et al. Vaccine-derived neutralizing antibodies to the human cytomegalovirus gH/gL pentamer potently block primary cytotrophoblast infection. J Virol. 2015;89(23):11884–11898.
   PubMed Web of Science ®Google Scholar
• Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A. 2005;102(50):18153–18158.
   PubMed Web of Science ®Google Scholar
• Cui X, Meza BP, Adler SP, et al. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine. 2008;26(45):5760–5766.
   PubMed Web of Science ®Google Scholar
• Fouts AE, Chan P, Stephan JP, et al. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol. 2012;86(13):7444–7447.
   PubMed Web of Science ®Google Scholar
• Lilleri D, Kabanova A, Revello MG, et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One. 2013;8(3):e59863.
   PubMed Web of Science ®Google Scholar
• Wussow F, Chiuppesi F, Meng Z, et al. Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex. J Virol Methods. 2018;251:30–37.
   PubMed Web of Science ®Google Scholar
• Chiuppesi F, Wussow F, Scharf L, et al. Comparison of homologous and heterologous prime-boost vaccine approaches using modified vaccinia ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice. PLoS One. 2017;12(8):e0183377.
   PubMed Web of Science ®Google Scholar
• Hofmann I, Wen Y, Ciferri C, et al. Expression of the human cytomegalovirus pentamer complex for vaccine use in a CHO system. Biotechnol Bioeng. 2015;112(12):2505–2515.
   PubMed Web of Science ®Google Scholar
• Wen Y, Monroe J, Linton C, et al. Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine. 2014;32(30):3796–3804.
   PubMed Web of Science ®Google Scholar
• John S, Yuzhakov O, Woods A, et al. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018;36(12):1689–1699.
   PubMed Web of Science ®Google Scholar
• Sanchez-Sampedro L, Perdiguero B, Mejias-Perez E, et al. The evolution of poxvirus vaccines. Viruses. 2015;7(4):1726–1803.
   PubMed Web of Science ®Google Scholar
• Overton ET, Stapleton J, Frank I, et al. Safety and immunogenicity of modified vaccinia ankara-bavarian nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial. Open Forum Infect Dis. 2015;2(2):ofv040.
   PubMed Web of Science ®Google Scholar
• Chiuppesi F, Nguyen J, Park S, et al. Multi-antigenic modified vaccinia ankara vaccine vectors to elicit potent humoral and cellular immune reponses against human cytomegalovirus in Mice. J Virol. 2018.
   PubMed Web of Science ®Google Scholar
• Schneider-Ohrum K, Cayatte C, Liu Y, et al. Production of cytomegalovirus dense bodies by scalable bioprocess methods maintains immunogenicity and improves neutralizing antibody titers. J Virol. 2016;90(22):10133–10144.
   PubMed Web of Science ®Google Scholar
• Kirchmeier M, Fluckiger AC, Soare C, et al. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity. Clin Vaccine Immunol. 2014;21(2):174–180.
   PubMed Web of Science ®Google Scholar
• Smith LR, Wloch MK, Chaplin JA, et al. Clinical development of a cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial. Vaccines (Basel). 2013;1(4):398–414.
   PubMedGoogle Scholar
• Schleiss MR, Berka U, Watson E, et al. Additive protection against congenital cytomegalovirus conferred by combined glycoprotein B/pp65 vaccination using a lymphocytic choriomeningitis virus vector. Clin Vaccine Immunol. 2017;24:1.
   Web of Science ®Google Scholar
• Zhong J, Khanna R. Delineating the role of CD4+ T cells in the activation of human cytomegalovirus-specific immune responses following immunization with Ad-gBCMVpoly vaccine: implications for vaccination of immunocompromised individuals. J Gen Virol. 2010;91(Pt 12):2994–3001.
   PubMedGoogle Scholar
• Adler SP, Plotkin SA, Gonczol E, et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis. 1999;180(3):843–846.
   PubMed Web of Science ®Google Scholar
• Berencsi K, Gyulai Z, Gonczol E, et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis. 2001;183(8):1171–1179.
   PubMed Web of Science ®Google Scholar
• Wilson SR, Wilson JH, Buonocore L, et al. Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity. Comp Med. 2008;58(2):129–139.
   PubMed Web of Science ®Google Scholar
• Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood. 2007;110(8):3071–3077.
   PubMed Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2014;58(3):309–318.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+: CD8+composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–2138.
   PubMed Web of Science ®Google Scholar
• Rossig C, Bollard CM, Nuchtern JG, et al. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002;99(6):2009–2016.
   PubMed Web of Science ®Google Scholar
• Cooper LJ, Al-Kadhimi Z, Serrano LM, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood. 2005;105(4):1622–1631.
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264–1270.
   PubMed Web of Science ®Google Scholar
• Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050–6056.
   PubMed Web of Science ®Google Scholar
• Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160–1166.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley V, Hegde M, et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncology. 2017;3(8):1094–1101.
   PubMed Web of Science ®Google Scholar
• Cruz CR, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122(17):2965–2973.
   PubMed Web of Science ®Google Scholar
• Wang X, Wong CW, Urak R, et al. CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015;21(13):2993–3002.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Tashiro H, Omer B, et al. Vaccination targeting native receptors to enhance the function and proliferation of Chimeric Antigen Receptor (CAR)-modified T cells. Clin Cancer Res: Off J Am Assoc Cancer Res. 2017;23(14):3499–3509.
   PubMed Web of Science ®Google Scholar
• Ma CKK, Clancy L, Simms R, et al. Adjuvant peptide pulsed dendritic cell vaccination in addition to T cell adoptive immunotherapy for cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2018;24(1):71–77.
   PubMed Web of Science ®Google Scholar
• Roep BO, Tree TI. Immune modulation in humans: implications for type 1 diabetes mellitus. Nat Rev Endocrinol. 2014;10(4):229–242.
   PubMed Web of Science ®Google Scholar
• Tsai S, Shameli A, Yamanouchi J, et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity. 2010;32(4):568–580.
   PubMed Web of Science ®Google Scholar
• Kleijwegt FS, Roep BO. Infectious tolerance as candidate therapy for type 1 diabetes: transfer of immunoregulatory properties from human regulatory T cells to other T cells and proinflammatory dendritic cells. Crit Rev Immunol. 2013;33(5):415–434.
   PubMed Web of Science ®Google Scholar
• Schleiss MR, McGregor A, Choi KY, et al. Analysis of the nucleotide sequence of the guinea pig cytomegalovirus (GPCMV) genome. Virol J. 2008;5:139.
   PubMed Web of Science ®Google Scholar
• Rawlinson WD, Farrell HE, Barrell BG. Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol. 1996;70(12):8833–8849.
   PubMed Web of Science ®Google Scholar
• Hansen SG, Strelow LI, Franchi DC, et al. Complete sequence and genomic analysis of rhesus cytomegalovirus. J Virol. 2003;77(12):6620–6636.
   PubMed Web of Science ®Google Scholar
• Vink C, Beuken E, Bruggeman CA. Complete DNA sequence of the rat cytomegalovirus genome. J Virol. 2000;74(16):7656–7665.
   PubMed Web of Science ®Google Scholar
• Geyer H, Ettinger J, Moller L, et al. Rat cytomegalovirus (RCMV) English isolate and a newly identified Berlin isolate share similarities with but are separate as an anciently diverged clade from mouse CMV and the Maastricht isolate of RCMV. J Gen Virol. 2015;96(Pt 7):1873.
   PubMedGoogle Scholar
• Crawford LB, Tempel R, Streblow DN, et al. Human cytomegalovirus induces cellular and humoral virus-specific immune responses in humanized BLT Mice. Sci Rep. 2017;7(1):937.
   PubMedGoogle Scholar
• Mocarski ES, Bonyhadi M, Salimi S, et al. Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication. Proc Natl Acad Sci U S A. 1993;90(1):104–108.
   PubMed Web of Science ®Google Scholar
• Reddehase MJ, Podlech J, Grzimek NK. Mouse models of cytomegalovirus latency: overview. J Clin Virol: Off Publ Pan Am Soc Clin Virol. 2002;25(Suppl 2):S23–36.
   Google Scholar
• Krmpotic A, Bubic I, Polic B, et al. Pathogenesis of murine cytomegalovirus infection. Microbes Infect. 2003;5(13):1263–1277.
   PubMed Web of Science ®Google Scholar
• Volkmer H, Bertholet C, Jonjic S, et al. Cytolytic T lymphocyte recognition of the murine cytomegalovirus nonstructural immediate-early protein pp89 expressed by recombinant vaccinia virus. J Exp Med. 1987;166(3):668–677.
   PubMed Web of Science ®Google Scholar
• Del Val M, Schlicht HJ, Volkmer H, et al. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol. 1991;65(7):3641–3646.
   PubMed Web of Science ®Google Scholar
• Scalzo AA, Elliott SL, Cox J, et al. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J Virol. 1995;69(2):1306–1309.
   PubMed Web of Science ®Google Scholar
• Reddehase MJ, Koszinowski UH. Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature. 1984;312(5992):369–371.
   PubMed Web of Science ®Google Scholar
• Reddehase MJ, Mutter W, Munch K, et al. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol. 1987;61(10):3102–3108.
   PubMed Web of Science ®Google Scholar
• Reddehase MJ, Rothbard JB, Koszinowski UH. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature. 1989;337(6208):651–653.
   PubMed Web of Science ®Google Scholar
• Morello CS, Cranmer LD, Spector DH. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65). J Virol. 2000;74(8):3696–3708.
   PubMed Web of Science ®Google Scholar
• Ye M, Morello CS, Spector DH. Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge. J Virol. 2002;76(5):2100–2112.
   PubMed Web of Science ®Google Scholar
• Morello CS, Ye M, Spector DH. Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication. J Virol. 2002;76(10):4822–4835.
   PubMed Web of Science ®Google Scholar
• Morello CS, Ye M, Hung S, et al. Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge. J Virol. 2005;79(1):159–175.
   PubMed Web of Science ®Google Scholar
• Reddehase MJ. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol. 2002;2(11):831–844.
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Hill AB. Viral interference with antigen presentation. Nat Immunol. 2002;3(11):1019–1025.
   PubMed Web of Science ®Google Scholar
• Holtappels R, Podlech J, Pahl-Seibert MF, et al. Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues. J Exp Med. 2004;199(1):131–136.
   PubMed Web of Science ®Google Scholar
• Morello CS, Kelley LA, Munks MW, et al. DNA immunization using highly conserved murine cytomegalovirus genes encoding homologs of human cytomegalovirus UL54 (DNA polymerase) and UL105 (helicase) elicits strong CD8 T-cell responses and is protective against systemic challenge. J Virol. 2007;81(14):7766–7775.
   PubMed Web of Science ®Google Scholar
• Munks MW, Gold MC, Zajac AL, et al. Genome-wide analysis reveals a highly diverse CD8 T cell response to murine cytomegalovirus. J Immunology. 2006;176(6):3760–3766.
   PubMed Web of Science ®Google Scholar
• Orloff SL, Hwee YK, Kreklywich C, et al. Cytomegalovirus latency promotes cardiac lymphoid neogenesis and accelerated allograft rejection in CMV naive recipients. Am J Transplantation: off J Am Soc Transplant Am Soc Transpl Surgeons. 2011;11(1):45–55.
   Google Scholar
• Streblow DN, Hwee YK, Kreklywich CN, et al. Rat cytomegalovirus vaccine prevents accelerated chronic rejection in CMV-naive recipients of infected donor allograft hearts. Am J Transplantation: off J Am Soc Transplant Am Soc Transpl Surgeons. 2015;15(7):1805–1816.
   Google Scholar
• Gao L, Qian S, Zeng L, et al. An animal model of human cytomegalovirus infection. Transplant Proc. 2007;39(10):3438–3443.
   PubMed Web of Science ®Google Scholar
• Isom HC, Gao M, Wigdahl B. Characterization of guinea pig cytomegalovirus DNA. J Virol. 1984;49(2):426–436.
   PubMed Web of Science ®Google Scholar
• Gao M, Isom HC. Characterization of the guinea pig cytomegalovirus genome by molecular cloning and physical mapping. J Virol. 1984;52(2):436–447.
   PubMed Web of Science ®Google Scholar
• Schleiss MR. Animal models of congenital cytomegalovirus infection: an overview of progress in the characterization of guinea pig cytomegalovirus (GPCMV). J Clin Virol: Off Publ Pan Am Soc Clin Virol. 2002;25(Suppl 2):S37–49.
   Google Scholar
• McGregor A, Schleiss MR. Molecular cloning of the guinea pig cytomegalovirus (GPCMV) genome as an infectious bacterial artificial chromosome (BAC) in escherichia coli. Mol Genet Metab. 2001;72(1):15–26.
   PubMed Web of Science ®Google Scholar
• Cui X, McGregor A, Schleiss MR, et al. Cloning the complete guinea pig cytomegalovirus genome as an infectious bacterial artificial chromosome with excisable origin of replication. J Virol Methods. 2008;149(2):231–239.
   PubMed Web of Science ®Google Scholar
• Nozawa N, Yamamoto Y, Fukui Y, et al. Identification of a 1.6 kb genome locus of guinea pig cytomegalovirus required for efficient viral growth in animals but not in cell culture. Virology. 2008;379(1):45–54.
   PubMed Web of Science ®Google Scholar
• Yamada S, Nozawa N, Katano H, et al. Characterization of the guinea pig cytomegalovirus genome locus that encodes homologs of human cytomegalovirus major immediate-early genes, UL128, and UL130. Virology. 2009;391(1):99–106.
   PubMed Web of Science ®Google Scholar
• Padilla-Carlin DJ, McMurray DN, Hickey AJ. The guinea pig as a model of infectious diseases. Comp Med. 2008;58(4):324–340.
   PubMed Web of Science ®Google Scholar
• Yang D, Alam Z, Cui X, et al. Complete genome sequence of cell culture-attenuated guinea pig cytomegalovirus cloned as an infectious bacterial artificial chromosome. Genome Announc. 2014;2:5.
   Google Scholar
• Bia FJ, Griffith BP, Fong CK, et al. Cytomegaloviral infections in the guinea pig: experimental models for human disease. Rev Infect Dis. 1983;5(2):177–195.
   PubMedGoogle Scholar
• Griffith BP, McCormick SR, Fong CK, et al. The placenta as a site of cytomegalovirus infection in guinea pigs. J Virol. 1985;55(2):402–409.
   PubMed Web of Science ®Google Scholar
• Mess A. The Guinea pig placenta: model of placental growth dynamics. Placenta. 2007;28(8–9):812–815.
   PubMed Web of Science ®Google Scholar
• Enders AC, Comparative A. Study of the fine structure of the trophoblast in several hemochorial placentas. Am J Anat. 1965;116:29–67.
   PubMedGoogle Scholar
• Carter AM. Animal models of human placentation–a review. Placenta. 2007;28(Suppl A):S41–47.
   PubMed Web of Science ®Google Scholar
• Medearis DN Jr. Mouse cytomegalovirus infection. 3. attempts to produce intrauterine infections. Am J Hyg. 1964;80:113–120.
   PubMedGoogle Scholar
• Griffith BP, Lucia HL, Hsiung GD. Brain and visceral involvement during congenital cytomegalovirus infection of guinea pigs. Pediatr Res. 1982;16(6):455–459.
   PubMed Web of Science ®Google Scholar
• Woolf NK, Koehrn FJ, Harris JP, et al. Congenital cytomegalovirus labyrinthitis and sensorineural hearing loss in guinea pigs. J Infect Dis. 1989;160(6):929–937.
   PubMed Web of Science ®Google Scholar
• Katano H, Sato Y, Tsutsui Y, et al. Pathogenesis of cytomegalovirus-associated labyrinthitis in a guinea pig model. Microbes Infect. 2007;9(2):183–191.
   PubMed Web of Science ®Google Scholar
• Swanson EC, Gillis P, Hernandez-Alvarado N, et al. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality. Vaccine. 2015;33(32):4013–4018.
   PubMed Web of Science ®Google Scholar
• Hornig J, Choi KY, McGregor A. The essential role of guinea pig cytomegalovirus (GPCMV) IE1 and IE2 homologs in viral replication and IE1-mediated ND10 targeting. Virology. 2017;504:122–140.
   PubMed Web of Science ®Google Scholar
• Cardin RD, Bravo FJ, Pullum DA, et al. Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection. Vaccine. 2016;34(17):1993–1999.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Yamada S, Katano H, et al. Effects of immunization of pregnant guinea pigs with guinea pig cytomegalovirus glycoprotein B on viral spread in the placenta. Vaccine. 2013;31(31):3199–3205.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Yan D, Fouts A, et al. Characterization of the guinea pig CMV gH/gL/GP129/GP131/GP133 complex in infection and spread. Virology. 2013;441(1):75–84.
   PubMed Web of Science ®Google Scholar
• Coleman S, Choi KY, Root M, et al. Complex dictates viral epithelial tropism, pathogenicity and congenital infection rate in guinea pig cytomegalovirus. PLoS Pathog. 2016;12(7):e1005755.
   PubMed Web of Science ®Google Scholar
• Yamada S, Katano H, Sato Y, et al. An Ex vivo culture model for placental cytomegalovirus infection using slices of guinea pig placental tissue. Placenta. 2016;37:85–88.
   PubMed Web of Science ®Google Scholar
• Ryckman BJ, Chase MC, Johnson DC. HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors. Proc Natl Acad Sci U S A. 2008;105(37):14118–14123.
   PubMed Web of Science ®Google Scholar
• McVoy MA, Wang JB, Dittmer DP, et al. Repair of a mutation disrupting the guinea pig cytomegalovirus pentameric complex acquired during fibroblast passage restores pathogenesis in immune-suppressed guinea pigs and in the context of congenital infection. J Virol. 2016;90(17):7715–7727.
   PubMed Web of Science ®Google Scholar
• Ha S, Li F, Troutman MC, et al. Neutralization of diverse human cytomegalovirus strains conferred by antibodies targeting viral gH/gL/pUL128-131 pentameric complex. J Virol. 2017;91:7.
   Web of Science ®Google Scholar
• Wussow F, Yue Y, Martinez J, et al. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J Virol. 2013;87(3):1322–1332.
   PubMed Web of Science ®Google Scholar
• Bourne N, Schleiss MR, Bravo FJ, et al. Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection. J Infect Dis. 2001;183(1):59–64.
   PubMed Web of Science ®Google Scholar
• Yue Y, Barry PA. Rhesus cytomegalovirus a nonhuman primate model for the study of human cytomegalovirus. Adv Virus Res. 2008;72:207–226.
   PubMed Web of Science ®Google Scholar
• Powers CJ, Fruh K. Signal peptide-dependent inhibition of MHC class I heavy chain translation by rhesus cytomegalovirus. PLoS Pathog. 2008;4(10):e1000150.
   PubMed Web of Science ®Google Scholar
• Bialas KM, Tanaka T, Tran D, et al. Maternal CD4+ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission. Proc Natl Acad Sci U S A. 2015;112(44):13645–13650.
   PubMed Web of Science ®Google Scholar
• Lockridge KM, Zhou SS, Kravitz RH, et al. Primate cytomegaloviruses encode and express an IL-10-like protein. Virology. 2000;268(2):272–280.
   PubMed Web of Science ®Google Scholar
• Itell HL, Kaur A, Deere JD, et al. Rhesus monkeys for a nonhuman primate model of cytomegalovirus infections. Curr Opin Virol. 2017;25:126–133.
   PubMed Web of Science ®Google Scholar
• Fowler KB, Stagno S, Pass RF, et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med. 1992;326(10):663–667.
   PubMed Web of Science ®Google Scholar
• Nelson CS, Cruz DV, Tran D, et al. Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys. JCI Insight. 2017;2:13.
   Web of Science ®Google Scholar
• Dela Pena MG, Strelow L, Barry PA, et al. Use of specific-pathogen-free (SPF) rhesus macaques to better model oral pediatric cytomegalovirus infection. J Med Primatol. 2012;41(3):225–229.
   PubMed Web of Science ®Google Scholar
• Powers C, Fruh K. Rhesus CMV: an emerging animal model for human CMV. Med Microbiol Immunol. 2008;197(2):109–115.
   PubMed Web of Science ®Google Scholar
• Oxford KL, Strelow L, Yue Y, et al. Open reading frames carried on UL/b’ are implicated in shedding and horizontal transmission of rhesus cytomegalovirus in rhesus monkeys. J Virol. 2011;85(10):5105–5114.
   PubMed Web of Science ®Google Scholar
• Oxford KL, Eberhardt MK, Yang KW, et al. Protein coding content of the UL)b’ region of wild-type rhesus cytomegalovirus. Virology. 2008;373(1):181–188.
   PubMed Web of Science ®Google Scholar
• Lilja AE, Shenk T. Efficient replication of rhesus cytomegalovirus variants in multiple rhesus and human cell types. Proc Natl Acad Sci U S A. 2008;105(50):19950–19955.
   PubMed Web of Science ®Google Scholar
• Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st century: a tool for decisionmaking. In: Stratton KR, Durch JS, Lawrence RS, editors. Vaccines for the 21st century: a tool for decisionmaking. Washington (DC); 2000.
   Google Scholar
• Anderholm KM, Bierle CJ, Schleiss MR. Cytomegalovirus vaccines: current status and future prospects. Drugs. 2016;76(17):1625–1645.
   PubMed Web of Science ®Google Scholar
• Baraniak I, Kropff B, McLean GR, et al. Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: anti-AD2 levels correlate with protection from viremia. J Infect Dis. 2018;217(12):1907–1917.
   PubMed Web of Science ®Google Scholar
• Schleiss MR. Searching for a serological correlate of protection for a CMV vaccine. J Infect Dis. 2018;217(12):1861–1864.
   PubMed Web of Science ®Google Scholar
• Baraniak IA, Reeves MB, Griffiths PD. Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient. Rev Med Virol. 2018;28:1.
   Web of Science ®Google Scholar
• Boppana SB, Britt WJ. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis. 1995;171(5):1115–1121.
   PubMed Web of Science ®Google Scholar
• Lilleri D, Kabanova A, Lanzavecchia A, et al. Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol. 2012;32(6):1324–1331.
   PubMed Web of Science ®Google Scholar
• Fornara C, Furione M, Arossa A, et al. Comparative magnitude and kinetics of human cytomegalovirus-specific CD4(+) and CD8(+) T-cell responses in pregnant women with primary versus remote infection and in transmitting versus non-transmitting mothers: its utility for dating primary infection in pregnancy. J Med Virol. 2016;88(7):1238–1246.
   PubMed Web of Science ®Google Scholar
• Nigro G, Adler SP, La Torre R, et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005;353(13):1350–1362.
   PubMed Web of Science ®Google Scholar
• Revello MG, Lazzarotto T, Guerra B, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014;370(14):1316–1326.
   PubMed Web of Science ®Google Scholar
• Schleiss MR, McVoy MA. Guinea pig cytomegalovirus (GPCMV): A model for the study of the prevention and treatment of maternal-fetal transmission. Future Virol. 2010;5(2):207–217.
   PubMed Web of Science ®Google Scholar
• Auerbach MR, Yan D, Vij R, et al. A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection. PLoS Pathog. 2014;10(4):e1004060.
   PubMed Web of Science ®Google Scholar
• Schleiss MR, Choi KY, Anderson J, et al. Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model. Vaccine. 2014;32(23):2756–2762.
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Harrison CJ, Britt WJ, et al. Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J Infect Dis. 2001;183(11):1547–1553.
   PubMed Web of Science ®Google Scholar
• Boppana SB, Rivera LB, Fowler KB, et al. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001;344(18):1366–1371.
   PubMed Web of Science ®Google Scholar
• Britt WJ. Congenital human cytomegalovirus infection and the enigma of maternal immunity. J Virol. 2017;91:15.
   Web of Science ®Google Scholar
• Wang C, Zhang X, Bialek S, et al. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;52(2):e11–13.
   PubMed Web of Science ®Google Scholar